TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07316062: A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China

Sponsor: AstraZeneca · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 3000 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07316062 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07316062 Rescue Dossier →